Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Arch Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$6,248,747

320 payments

Through program year 2025, Arch Clinical Trials LLC is reported as receiving $6,248,747 in research payments, across 320 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $433,838 37
2024 Research $750,313 61
2023 Research $2,243,170 127
2022 Research $2,090,056 69
2021 Research $601,768 17
2020 Research $110,015 7
2019 Research $19,586 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $1,920,975 143 payments
  2. ITI, Inc. $1,721,871 54 payments
  3. Sumitomo Pharma America, Inc. $986,397 44 payments
  4. Eli Lilly and Company $764,451 9 payments
  5. Sunovion Pharmaceuticals Inc. $359,388 11 payments
  6. AbbVie, Inc. $195,641 20 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $135,207 10 payments
  8. Sage Therapeutics, Inc. $64,774 15 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $39,575 1 payment
  10. GW Research Limited $37,119 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $1,920,975 143 payments
  2. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia $1,721,871 54 payments
  3. A Randomized Double-blind Parallel-group Placebocontrolled Fixed-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia $908,735 16 payments
  4. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $604,425 7 payments
  5. A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $339,734 9 payments
  6. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $160,026 2 payments
  7. Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $114,654 9 payments
  8. A Study to Evaluate the Efficacy and Safety of Sage-217 in Participants With Severe Postpartum Depression (PPD) $64,774 15 payments
  9. A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $62,215 3 payments
  10. An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia $55,518 26 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record